Cancer Therapy
RNA interference stops breast cancer cell proliferation and invasiveness
Published in Gene Therapy Weekly, May 19th, 2005
"Overexpression of RhoA or RhoC in breast cancer indicates a poor prognosis, due to increased tumor cell proliferation and invasion and tumor-dependent angiogenesis. Until now, the strategy of blockage of the Rho-signaling pathway has used either GGTI or HMG-CoA reductase inhibitors, but they are not specific to RhoA or RhoC inhibition. In this study, a new approach with anti-RhoA and anti-RhoC siRNAs was used to inhibit specifically RhoA or RhoC synthesis," scientists in France report.
"Two transfections of either RhoA or RhoC siRNA (8.5 nM) into MDA-MB-231 human breast cancer...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2005-05-19)
More Articles from Gene Therapy Weekly
- Bone Cancer
Liposome complexes containing endostatin abate osteosarcoma metastasis - Gastroenterology
Carboxylesterase-2 gene therapy sensitizes colon cancer cells to chemotherapy - Oncology
4T1 tumor cells determine the true fate of cancer gene therapy - Stroke
Midkine gene transfer protects brain cells against focal ischemia - Virology
Inactivated adenoviruses in microbead conjugates transfect targeted cells - Acute Lymphoblastic Leukemia
RAS mutation associated with hyperdiploidy/parental characteristics in ALL - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
